SCHEMBL4013528

SCHEMBL4013528

COc1ccc(/C=C/C(=O)NCCc2c(C)[nH]c3c(F)ccc(F)c23)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
POLB P06746 1/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
RAB9A P51151 1/20 0.47
GAA P10253 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HPGD P15428 1/20 0.45
LY96 Q9Y6Y9 1/20 0.44
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4015557 0.94 POLB (0.49) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4015555 0.94 POLB (0.49) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL13965458 0.87 MEN1 (0.44) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4669271 0.84 KMT2A (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4754381 0.84 KMT2A (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4017819 0.84 MEN1 (0.47) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4669514 0.83 MEN1 (0.46) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4754393 0.83 MEN1 (0.46) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4017504 0.83 HPGD (0.53) MAPTPOLBKMT2AMEN1ALDH1A1
SCHEMBL4017506 0.83 HPGD (0.53) MAPTPOLBKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
EP-2014287-A1 Use of cinnamic acid derivatives as modulators of an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed